Novel approaches to the treatment of thrombosis

Trends in Pharmacological Sciences

Volumn 23, Issue 1, 2002, Pages 25-32

  Gresele, Paolo ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; APYRASE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; COLLAGEN; DERMATAN; HEPARIN DERIVATIVE; HIRUDIN; NITRIC OXIDE; PROSTACYCLIN; PROTEIN C; THROMBIN INHIBITOR; THROMBIN RECEPTOR; THROMBOMODULIN; TICLOPIDINE; VON WILLEBRAND FACTOR; WARFARIN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DOWN REGULATION; HEMOSTASIS; HUMAN; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DRUGS, INVESTIGATIONAL; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0036165065     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01885-X     Document Type: Review

References (70)

1. Mortality by cause for eight regions of the world; global burden of disease study
2. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high risk patients
3. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling
4. Collagen receptor signalling in platelets and megakaryocytes
5. Platelet collagen receptors: A new target for inhibition?
6. Alboaggregin A activates platelets by a mechanism involving glycoprotein VI as well as glycoprotein Ib
7. 1 integrin to the induction of platelet protein tyrosine phosphorylation and aggregation
8. A revised model of platelet aggregation
9. Tissue factor pathway inhibitor
10. The protein C pathway: New insights
11. The plasminogen (fibrinolytic) system
12. Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig
13. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in non human primates
14. Anti human von Willebrand factor monoclonal antibody. AjvW-2 prevents thrombus deposition and neointima formation after baloon injury in guinea pigs
15. 728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX
16. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model
17. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis and delays coronary artery occlusion in dogs
18. Abolition of cyclic flow variations in stenosed endothelium-injured coronary arteries in non human primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib domain
19. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries
20. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo
21. Aurintricarboxylic acid prevents acute rethrombosis in a canine model of arterial thrombosis
22. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery
23. Flavone-8-acetic acid (flavonoid) profoundly reduces platelet-dependent thrombosis and vasoconstriction after deep arterial injury in vivo
24. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. II. Cloning of the cDNA and expression
25. Cloning of the cDNA and expression of moubatin, an inhibitor of platelet aggregation
26. An inhibitor of collagen-induced platelet aggregation from the saliva of triatoma pallidipennis
27. 1 (GPIa/IIa)-I-domain binding to collagen in a different manner
28. Calin from hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters
29. Pallipidin, a selective inhibitor of collagen-induced platelet aggregation, prevents platelet pulmonary embolism in mice by inducing only a mild haemostatic defect
30. Recombinant leech antiplatelet protein prevents collagen-madiated platelet aggregation but not collagen graft thrombosis in baboons
31. 1
32. 1 integrin is essential for platelet interaction with collagen
33. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice
34. The platelet collagen receptor GPVI is a member of the immunoglobulin superfamily closely related to FcγR and the natural killer receptors
35. How the protease thrombin talks to cells
36. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the african green monkey
37. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor
38. Protease-activated receptor 1 and 4 are shut off with distinct kinetics after activation by thrombin
39. Thrombostatin inhibits induced canine coronary thrombosis
40. YD-3, a novel inhibitor of protease-induced platelet activation
41. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature
42. Deficient platelet derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene
43. NO-aspirins, a class of new anti-inflammatory and antithrombotic agents
44. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide releasing aspirin
45. Effects of nitric oxide releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice
46. Antithrombotic and vasorelaxant properties of a novel synthetic RGD peptide containing nitric oxide
47. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model
48. ADP receptors and their inhibition
49. Key role of the P2Y1 receptor in tissue factor-induced thrombin-dependent acute thromboembolism: Studies in P2Y1-knockout mice and mice treated with a P2Y1 antagonist
50. Role of tissue factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon
51. Antithrombotic and anti-lesion benefits without hemorrhagic risk by inhibiting tissue factor pathway
52. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa
53. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in the prevention of post-operative venous thromboembolism in patients undergoing total knee replacement
54. Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa
55. Isolation and characterization of antistasin
56. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech
57. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies
58. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
59. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer: DOS (Dermatan sulphate in Oncologic surgery) Study Group
60. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate: Pharmacologic considerations
61. Design and synthesis of potent and highly selective thrombin inhibitors
62. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis: ADVENT Investigators
63. Pharmacodynamic properties of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use
64. Intravenous treatment of acute deep vein thrombosis (DVT) with melagatran, a synthetic low molecular weight thrombin inhibitor
65. Pharmacological profile of recombinant human activated protein C (LY203638) in a canine model of coronary artery thrombosis
66. Activated human protein C prevents thrombin induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation
67. Prevention of arterial reocclusion after thrombosis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis
68. Efficacy and safety of recombinant human activated protein C for severe sepsis
69. ART-123: Recombinant human soluble thrombomodulin
70. Recombinant soluble thrombomodulin prevents thrombin-induced thromboembolism in mice independently of direct thrombin inihibition